Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103


Development of a novel orthotopic non-small cell lung cancer model and therapeutic benefit of 2'-(2-bromohexadecanoyl)-docetaxel conjugate nanoparticles.

Peng L, Feng L, Yuan H, Benhabbour SR, Mumper RJ.

Nanomedicine. 2014 Oct;10(7):1497-506. doi: 10.1016/j.nano.2014.03.016. Epub 2014 Apr 4.


2'-(2-bromohexadecanoyl)-paclitaxel conjugate nanoparticles for the treatment of non-small cell lung cancer in an orthotopic xenograft mouse model.

Peng L, Schorzman AN, Ma P, Madden AJ, Zamboni WC, Benhabbour SR, Mumper RJ.

Int J Nanomedicine. 2014 Jul 30;9:3601-10. doi: 10.2147/IJN.S66040. eCollection 2014.


Oil-filled lipid nanoparticles containing 2'-(2-bromohexadecanoyl)-docetaxel for the treatment of breast cancer.

Feng L, Benhabbour SR, Mumper RJ.

Adv Healthc Mater. 2013 Nov;2(11):1451-7. doi: 10.1002/adhm.201300017. Epub 2013 Apr 19.


Pre-clinical validation of orthotopically-implanted pulmonary tumor by imaging with 18F-fluorothymidine-positron emission tomography/computed tomography.

Fushiki H, Miyoshi S, Noda A, Murakami Y, Sasaki H, Jitsuoka M, Mitsuoka K, Matsunari I, Nishimura S.

Anticancer Res. 2013 Nov;33(11):4741-9.


Non-invasive monitoring of anticancer effects of cisplatin on lung cancer in an orthotopic SCID mouse model using [¹⁸F] FDG PET-CT.

Mokhtar M, Kondo K, Takizawa H, Ohtani T, Otsuka H, Kubo H, Kajiura K, Nakagawa Y, Kawakami Y, Yoshida M, Fujino H, Sakiyama S, Tangoku A.

Oncol Rep. 2014 May;31(5):2007-14. doi: 10.3892/or.2014.3056. Epub 2014 Mar 5.


Development and optimization of oil-filled lipid nanoparticles containing docetaxel conjugates designed to control the drug release rate in vitro and in vivo.

Feng L, Wu H, Ma P, Mumper RJ, Benhabbour SR.

Int J Nanomedicine. 2011;6:2545-56. doi: 10.2147/IJN.S24954. Epub 2011 Oct 21.


Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.

Pectasides D, Pectasides M, Farmakis D, Kostopoulou V, Nikolaou M, Gaglia A, Koumpou M, Mylonakis N, Xiros N, Economopoulos T, Raptis SA.

Ann Oncol. 2005 Feb;16(2):294-9.


Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT(®) nanoparticle formulation against non-small-cell lung cancer brain metastases.

Sambade M, Deal A, Schorzman A, Luft JC, Bowerman C, Chu K, Karginova O, Swearingen AV, Zamboni W, DeSimone J, Anders CK.

Nanomedicine (Lond). 2016 Aug;11(15):1947-55. doi: 10.2217/nnm-2016-0147. Epub 2016 Jul 26.


Docetaxel-loaded PEG-albumin nanoparticles with improved antitumor efficiency against non-small cell lung cancer.

Jin G, Jin M, Jin Z, Gao Z, Yin X.

Oncol Rep. 2016 Aug;36(2):871-6. doi: 10.3892/or.2016.4863. Epub 2016 Jun 8.


Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival.

Whitehead CM, Earle KA, Fetter J, Xu S, Hartman T, Chan DC, Zhao TL, Piazza G, Klein-Szanto AJ, Pamukcu R, Alila H, Bunn PA Jr, Thompson WJ.

Mol Cancer Ther. 2003 May;2(5):479-88.


Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition.

Jiang Y, Yang N, Zhang H, Sun B, Hou C, Ji C, Zheng J, Liu Y, Zuo P.

J Control Release. 2016 Jan 10;221:26-36. doi: 10.1016/j.jconrel.2015.11.029. Epub 2015 Nov 28.


Phase II trial of biweekly chemotherapy with docetaxel and cisplatin in high-risk patients with unresectable non-small cell lung cancer.

Kim MJ, Kim SH, Kang JH, Kim HG, Cho YJ, Jeong YY, Kim HC, Lee JD, Hwang YS, Kim MG, Choi JY, Lee GW.

Chemotherapy. 2013;59(3):159-66. doi: 10.1159/000354983. Epub 2013 Oct 9.


Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).

Gervais R, Ducolone A, Breton JL, Braun D, Lebeau B, Vaylet F, Debieuvre D, Pujol JL, Tredaniel J, Clouet P, Quoix E.

Ann Oncol. 2005 Jan;16(1):90-6.


Pluronic P105/F127 mixed micelles for the delivery of docetaxel against Taxol-resistant non-small cell lung cancer: optimization and in vitro, in vivo evaluation.

Chen L, Sha X, Jiang X, Chen Y, Ren Q, Fang X.

Int J Nanomedicine. 2013;8:73-84. doi: 10.2147/IJN.S38221. Epub 2013 Jan 3.


Monitoring with a non-invasive bioluminescent in vivo imaging system of pleural metastasis of lung carcinoma.

Matsumoto S, Tanaka F, Sato K, Kimura S, Maekawa T, Hasegawa S, Wada H.

Lung Cancer. 2009 Oct;66(1):75-9. doi: 10.1016/j.lungcan.2008.12.010. Epub 2009 Jan 28.


Bioluminescent orthotopic mouse models of human localized non-small cell lung cancer: feasibility and identification of circulating tumour cells.

Mordant P, Loriot Y, Lahon B, Castier Y, Lesèche G, Soria JC, Vozenin MC, Decraene C, Deutsch E.

PLoS One. 2011;6(10):e26073. doi: 10.1371/journal.pone.0026073. Epub 2011 Oct 11.


Gelatinase-stimuli strategy enhances the tumor delivery and therapeutic efficacy of docetaxel-loaded poly(ethylene glycol)-poly(ɛ-caprolactone) nanoparticles.

Liu Q, Li RT, Qian HQ, Yang M, Zhu ZS, Wu W, Qian XP, Yu LX, Jiang XQ, Liu BR.

Int J Nanomedicine. 2012;7:281-95. doi: 10.2147/IJN.S26697. Epub 2012 Jan 20.


Monitoring of tumour progression using bioluminescence imaging and computed tomography scanning in a nude mouse orthotopic model of human small cell lung cancer.

Iochmann S, Lerondel S, Bléchet C, Lavergne M, Pesnel S, Sobilo J, Heuzé-Vourc'h N, Le Pape A, Reverdiau P.

Lung Cancer. 2012 Jul;77(1):70-6. doi: 10.1016/j.lungcan.2012.01.009. Epub 2012 Feb 8.


Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model.

Fulzele SV, Chatterjee A, Shaik MS, Jackson T, Singh M.

Pharm Res. 2006 Sep;23(9):2094-106. Epub 2006 Aug 11.

Supplemental Content

Support Center